Thermo Fisher Completes Large-Scale Proteomics Analysis for Parkinson’s Precision Medicine Initiative — Thermo Fisher Scientific Inc.

Event summary

Thermo Fisher completed Olink Explore HT proteomic analysis of 5,500 research samples from The Michael J. Fox Foundation’s Parkinson’s Precision Medicine Initiative (PPMI).
The resulting data is now available in PPMI’s open-access repository for global researchers.
Olink’s Proximity Extension Assay (PEA) technology was used to enable high-throughput proteomic analysis.
The project aims to advance precision medicine by studying Parkinson’s disease at the protein level.

The big picture

This collaboration underscores the growing importance of multi-omics approaches in neurodegenerative disease research, particularly as the field shifts toward biology-driven precision medicine. With an estimated 10 million people living with Parkinson’s disease globally, the need for reliable biomarkers and targeted therapies is critical. Thermo Fisher’s role in expanding proteomic analysis within PPMI highlights its strategic position in enabling large-scale molecular datasets that support biomarker discovery and precision medicine.

What we're watching

Data Utilization: How quickly and effectively the global research community leverages this proteomic dataset to identify biomarkers and uncover disease pathways.
Precision Medicine Advancement: Whether these insights will accelerate the development of targeted therapeutic approaches for Parkinson’s disease.
Technological Scalability: The pace at which Olink’s PEA technology can be adopted in other large-scale proteomic studies beyond Parkinson’s research.